EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study

Nuha Alsaleh iD, Noha A Seif-Eldein iD, Ahmed M El Malky iD, Hashem Al Hashem iD, Hend Idriss

World Journal of Surgery · 2026

DOI: 10.1002/wjs.70487 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift World Journal of Surgery, 2026. Verfasst von Nuha Alsaleh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly prescribed for diabetes and obesity, but their perioperative safety in breast cancer surgery remains uncertain. This study evaluated the association between perioperative GLP‐1 RA use and 30‐day postoperative outcomes after breast cancer surgery. Materials and Methods This retrospective cohort study included adults undergoing breast cancer surgery at a tertiary center (January 2024–August 2025). Exposure was active GLP‐1 RA use within 30 days preoperatively, verified via pharmacy records. The primary outcome was a composite 30‐day surgical morbidity endpoint (surgical site infection [SSI], flap necrosis ≥ grade II, seroma requiring aspiration, or implant/expander loss). Secondary outcomes included venous thromboembolism (VTE), readmission, reoperation, and length of stay. Multivariable regression and inverse probability of treatment weighting (IPTW) addressed confounding.

Results

The analytic cohort comprised 750 patients (209 exposed, 541 unexposed; median age 51 years). Exposed patients had higher body mass index and diabetes prevalence. After adjustment, GLP‐1 RA exposure was not associated with SSI (adjusted odds ratio [AOR] 1.28, 95% CI 0.81–2.03), seroma (AOR 1.22, 95% CI 0.83–1.79), or flap necrosis ≥ grade II (AOR 1.41, 95% CI 0.83–2.40). No secondary outcome showed independent association with exposure. Prolonged length of stay (≥ 3 days) occurred in 26.8% of patients overall and was attributable primarily to drain management requirements, extent of surgery, and metabolic comorbidity rather than GLP‐1 RA exposure.

Conclusion

Perioperative GLP‐1 RA use was not independently associated with increased short‐term complications after breast cancer surgery. Multicenter studies are needed to confirm safety across settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsPostoperative ComplicationsHypoglycemic AgentsMastectomyHumansFemaleRetrospective StudiesMiddle AgedAdultAgedLength of Stay

Stichwörter der Autor:innen

GLP‐1 receptor agonistsbreast cancer surgeryperioperative carepostoperative complicationsretrospective cohort studysurgical morbidity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • King Saud University Medical City, King Khalid University Hospital, Riyadh, Saudi Arabia.
  • Oncology Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Nuha Alsaleh, Noha A Seif-Eldein, Ahmed M El Malky, Hashem Al Hashem

Zitieren

APA

Alsaleh, N., Seif-Eldein, N. A., El Malky, A. M., Al Hashem, H., & Idriss, H. (2026). Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study. World Journal of Surgery. https://doi.org/10.1002/wjs.70487

Vancouver

Alsaleh N, Seif-Eldein NA, El Malky AM, Al Hashem H, Idriss H. Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study. World Journal of Surgery. 2026. doi:10.1002/wjs.70487

BibTeX
@article{Alsaleh2026,
  author = {Alsaleh, Nuha and Seif-Eldein, Noha A and El Malky, Ahmed M and Al Hashem, Hashem and Idriss, Hend},
  title = {Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study},
  journal = {World Journal of Surgery},
  year = {2026},
  doi = {10.1002/wjs.70487}
}
Kostenlos starten →